Compare · HYPR vs MDT
HYPR vs MDT
Side-by-side comparison of Hyperfine Inc. (HYPR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPR and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.97B, about 1026.3x HYPR ($104.2M).
- Over the past year, HYPR is up 31.3% and MDT is down 6.9% - HYPR leads by 38.1 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- MDT has more recent analyst coverage (25 ratings vs 4 for HYPR).
- Company
- Hyperfine Inc.
- Medtronic plc.
- Price
- $1.05-4.55%
- $83.58-0.25%
- Market cap
- $104.2M
- $106.97B
- 1M return
- -25.53%
- +4.16%
- 1Y return
- +31.25%
- -6.85%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 2
- Recent ratings
- 4
- 25
Hyperfine Inc.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest HYPR
- Hyperfine Announces European Launch of Next-Generation Swoop® System
- Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care
- Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
- SEC Form 4 filed by Director Wolterman Dan
- CFO and CAO Hale Brett sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 1.00% to 599,765 units (SEC Form 4)
- Chief Operating Officer Teisseyre Thomas sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 0.88% to 678,601 units (SEC Form 4) (withholding obligation)
- Hyperfine to Join Russell 2000® and Russell 3000® Indexes
- SEC Form 4 filed by Director Fattori Ruth A
- SEC Form 4 filed by Director Wolterman Dan
- SEC Form 4 filed by Director Dahldorf John T
Latest MDT
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 2,840 units of Ordinary Shares, decreasing direct ownership by 7% to 38,689 units (SEC Form 4)